Non-Peptide Vasopressin V1b Receptor Antagonists as Potential Drugs for the Treatment of Stress-Related Disorders

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|11|12|1549-1559

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.11, Iss.12, 2005-05, pp. : 1549-1559

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Vasopressin V1b Receptor as a Therapeutic Target in Stress-related Disorders

By  

Current Drug Targets-CNS & Neurological Disorders, Vol. 2, Iss. 3, 2003-06 ,pp. : 191-200

Bentham Science Publishers

Access to resources Recommend Favorite

Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists

By Thibonnier M.  

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 5, 1998-05 ,pp. : 729-740

Informa Healthcare

Access to resources Recommend Favorite

Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists

By Paranjape S.B.   Thibonnier M.  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 5, 2001-05 ,pp. : 825-834

Informa Healthcare

Access to resources Recommend Favorite

Recent discovery and development of non-peptide vasopressin V2 receptor agonists

By Kondo Kazumi  

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 8, 2002-08 ,pp. : 1249-1258

Informa Healthcare

Access to resources Recommend Favorite

Non-peptide Antagonists and Agonists of the Bradykinin B2 Receptor

By  

Current Medicinal Chemistry, Vol. 9, Iss. 9, 2002-05 ,pp. : 913-928

Bentham Science Publishers

Access to resources Recommend Favorite